MOLN MOLECULAR PARTNERS AG
Price Chart
Executive Summary
Molecular Partners announced trial-in-progress poster presentations at ASCO and SNMMI 2026 for its lead Radio-DARPin candidate MP0712 (DLL3-targeting, 212Pb-based) in a Phase 1/2a study for small cell lung cancer and other neuroendocrine cancers. Dosing is ongoing in the first cohort, and initial clinical data are expected in 2026. The filing is a routine clinical update with no new efficacy or safety data disclosed.
Actionable Insight
No new clinical data were released — the posters are trial-in-progress updates. The key catalyst to watch is the initial clinical data readout expected later in 2026. Until then, the stock is likely to trade on broader biotech sentiment and cash runway updates.
Key Facts
- MP0712 is a 212Pb-based Radio-DARPin Therapy targeting DLL3, expressed in >85% of SCLC tumors.
- Phase 1/2a study (NCT07278479) is actively recruiting, dosing ongoing in first cohort.
- Initial clinical data expected in 2026.
- Co-developed with strategic partner Orano Med.
- First patient imaging/dosimetry data presented at TWC January 2026 showed specific tumor uptake.
- Trial-in-progress posters at ASCO (May 30) and SNMMI (June 2) — no new data disclosed.
Financial Impact
No financial figures disclosed. Pre-revenue clinical-stage biotech.
Risk Factors
- Phase 1/2a data may show safety or efficacy issues.
- DLL3-targeting space is competitive (e.g., Amgen's tarlatamab).
- Pre-revenue company with no near-term revenue catalyst.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003818 |
| Document: f6k_060126.htm | 0001171843-26-003818 |
| Document: 0001171843-26-003818-index-headers.html | 0001171843-26-003818 |
| Document: 0001171843-26-003818-index.html | 0001171843-26-003818 |
| Document: 0001171843-26-003818.txt | 0001171843-26-003818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
6-K
| — | awaiting T+5 | — | — |
|
May 12, 2026
24d ago
|
6-K
| $4.00 $3.74 | ▼ −6.50% | ▼ −5.34% | $4.10 (+2.50%) |
|
May 1, 2026
5w ago
|
Press Release
| $4.24 $4.10 | ▼ −3.30% | ▼ −5.65% | $4.10 (−3.30%) |
|
Mar 30, 2026
9w ago
|
6-K
| $3.93 $3.87 | ▼ −1.53% | ▼ −5.83% | $4.10 (+4.32%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.22 $4.59 | ▲ +8.65% | ▲ +10.77% | $4.10 (−2.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access